0.15 billion! Wuxi AppTec invested in a French VC, adding to the European biomedical market.
① Wuxi Apptec plans to invest in the "Jeito II S.L.P." fund, with a total target scale not exceeding 1.2 billion euros, and the fund is expected to invest in 14-17 medical innovative startups. ② Previously, Wuxi Apptec planned to invest 10 million euros in another well-known biotechnology investment institution in Europe, focusing on early-stage biomedical companies in Europe.
How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.
① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.
Trending Industry Today: WUXI APPTEC Leads Gains In CRO Stocks
Will the indications of GLP-1 drugs expand to the field of PCOS? The era of three targets is about to arrive? | Industry Observation
①At the GLP-1 Drug Seminar (Chengdu session), participants discussed the global trend of GLP-1 drug research and development. ②Participants mentioned that the indications for GLP-1 drugs in the future may expand to areas such as PCOS and stroke. ③Drugs targeting GLP, GCG, and GIP receptors are beginning to rise.
Wuxi Apptec responds to "Evolution of Laws after Trump Takes Office": Currently no direct impact | Directly addressing the earnings conference
①The US presidential election does not have a direct impact on the ongoing legislative process of the biosafety law; ②In response to the uncertainty brought by Xavier Becerra's appointment as the US HHS Secretary, Wuxi AppTec emphasizes that "customer demands for cost, efficiency, and quality will not change"; ③As of the end of September, Wuxi AppTec's hand order is 43.82 billion yuan, a year-on-year increase of 35.2%.
Trending Industry Today: WUXI APPTEC Leads Losses In CRO Stocks